Patents by Inventor Vaishali SHAH

Vaishali SHAH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING AUTOIMMUNE DISEASE USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40L
    Publication number: 20230295321
    Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, Pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.
    Type: Application
    Filed: September 21, 2022
    Publication date: September 21, 2023
    Inventors: MAREK HONCZARENKO, VAISHALI SHAH, LIXIN LANG, URVI ARAS, DIANE SHEVELL, CHRISTINE KRATT, KAREN PRICE, SUZANNE SUCHARD
  • Methods of treating autoimmune disease using a domain antibody directed against CD40L
    Patent number: 11466091
    Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: October 11, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Marek Honczarenko, Vaishali Shah, Lixin Lang, Urvi Aras, Diane Shevell, Christine Kratt, Karen Price, Suzanne Suchard
  • METHODS OF TREATING AUTOIMMUNE DISEASE USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40L
    Publication number: 20200216552
    Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 9, 2020
    Inventors: Marek Honczarenko, Vaishali Shah, Lixin Lang, Urvi Aras, Diane Shevell, Christine Kratt, Karen Price, Suzanne Suchard
  • Method of using antibody polypeptides that antagonize CD40 to treat IBD
    Patent number: 10435475
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 8, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Marek Honczarenko, Vaishali Shah, Xiaoni Liu, Wendy L. Trigona, Rong Shi, Suzanne J. Suchard, Karen D. Price, Linda M. Gustavson
  • METHODS OF TREATING AUTOIMMUNE DISEASE USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40L
    Publication number: 20170306034
    Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.
    Type: Application
    Filed: September 10, 2015
    Publication date: October 26, 2017
    Inventors: Marek HONCZARENKO, Vaishali SHAH, Lixin LANG, Urvi ARAS, Diane SHEVELL, Christine KRATT, Karen PRICE, Suzanne SUCHARD